<pad> Studies were excluded if they lacked a comparison group in which efficacy of 3 doses of HPV vaccine against clinical endpoints was demonstrated in clinical trials (e.g., females aged 15 through 26 years).<unk> Evidence regarding a 3-dose schedule for HPV vaccine was reviewed previously (1,2).Quality of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.</s>